CLINICAL TRIALS

Ovarian Cancer Clinical Trials in Pennsylvania

10+ recruiting Ovarian Cancer trials in Pennsylvania, sourced from ClinicalTrials.gov.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

RECRUITINGPhase 2

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

NCT05887609 · Philadelphia
ACTIVE NOT RECRUITINGPhase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or

NCT05277051 · Philadelphia
ACTIVE NOT RECRUITINGPhase 3

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is

NCT04095364 · Allentown
RECRUITING

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) prog

NCT03452774 · Philadelphia
RECRUITINGPhase 2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study w

NCT06730347 · Pittsburgh
ACTIVE NOT RECRUITINGPhase 2

A Trial of Vigil for Participants With Ovarian Cancer

The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to ans

NCT02346747 · Abington
ACTIVE NOT RECRUITINGPhase 1

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated an

NCT05973487 · Pittsburgh
ACTIVE NOT RECRUITINGPhase 2

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase II clinical trial studies the effect of lenvatinib, pembrolizumab, and paclitaxel in treating patients with endometrial, epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (rec

NCT04781088 · Pittsburgh
ACTIVE NOT RECRUITINGPhase 2

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to small

NCT05467670 · Pittsburgh
ACTIVE NOT RECRUITINGPhase 2

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PL

NCT07109414 · Philadelphia

RECOMMENDED RESOURCES FOR OVARIAN CANCER

🧬

Color Health

CLIA Certified

Hereditary cancer genetic testing from $99. Understand your inherited risk for breast, ovarian, colon, and other cancers — with genetic counseling included.

Get Tested →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Ovarian Cancer clinical trials in Pennsylvania?

Yes. Clinicals AI lists 10+ recruiting Ovarian Cancer trials in Pennsylvania sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Ovarian Cancer trial in Pennsylvania?

Eligibility varies by study. Most trials require a confirmed Ovarian Cancer diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Ovarian Cancer clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.